- Our Focus
Seeing possibilities in ophthalmology
In 2016, 200 million patients worldwide were treated with Novartis ophthalmic products. As a leading ophthalmology company, we produce therapies that treat both front- and back-of-the-eye disorders, including retinal diseases, glaucoma, dry eye and other external eye diseases.
Novartis researchers make clinical tools to help retinitis pigmentosa patients.
We have pioneered treatments for many retinal diseases. One of our current focus areas is neovascular age-related macular degeneration (AMD), which affects an estimated 20 to 25 million people worldwide and is a leading cause of severe vision loss.
Dry Eye Diseases
Dry eye, a multifactorial disease of the ocular surface, impacts more than 344 million patients worldwide. Dry eye can result from a range of genetic diseases and inflammatory disorders, and patients experience a range of symptoms that can lead to impaired vision. While palliative treatments such as artificial tears provide transient relief, we are working on novel, target-specific therapies designed to address the root causes of the disorder.
Other External Eye Diseases, Including Presbyopia
We are investing in developing the first pharmaceutical treatment with potential disease-modifying activity for presbyopia, a disease that affects 85% of people over 45 years old. There are currently no disease-modifying pharmacological treatments available or in clinical development to reverse the loss of near-distance vision.
More than 60 million people globally are affected by glaucoma, which can lead to progressive damage of the optic nerve. We provide treatment options for patients living with glaucoma to reduce the burden of disease around the world.
People are visually impaired worldwide
Of vision problems worldwide can be avoided
Of people living with blindness are aged 50 and above
Of the world's visually impaired live in low-income settings